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the care of patients with malignant diseases, especially in Central
Eastern European countries with limited health resources. Objectives:
The aim of this research was to estimate the epidemiological and
quality measures and resource use indicators in Hungary in four
malignant conditions (breast, colorectal, lung, and prostate cancer)
from the National Health Insurance Fund (NHIF) database. Methods:
Survival and cost analyses were performed on the NHIF database.
Patient records containing the International Classiﬁcation of Diseases
(ICD) codes C50 (breast cancer), C18–C20 (colorectal cancer), C33–C34
(lung cancer), and C61 (prostate cancer) were considered eligible.
Inclusion criteria were at least two consecutive ICD codes between
2000 and 2012, with a minimum of 30-day difference, or one ICD code,
followed by patient death within 60 days. A total of 428,860 social
insurance numbers met inclusion criteria. Results: The number of
new cases was 6381 for breast cancer, 8457 for colorectal cancer, 8902ee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.03.020
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ndence to: András Inotai, Syreon Research Institutfor lung cancer, and 3419 for prostate cancer. The probability of 5-year
overall survival from the ﬁrst diagnosis was 75.2%, 41.3%, 17.1%, and
62.1%, respectively. Median time from ﬁrst diagnosis to treatment
initiation was less than 1 month in all conditions except for lung
cancer. The annual cost of treatment was €2585, €3165, €4157, and
€2834, respectively. Cost ﬁgures were compared with hemophilia as
benchmark (€8284). Conclusions: The results indicated that the data-
base of the Hungarian NHIF is suitable for real-world data analysis in
the ﬁeld of oncology and can support long-term evidence-based
policymaking.
Keywords: breast cancer, colorectal cancer, cost, evidence-based
policymaking, hemophilia, lung cancer, mortality, new cases, payer’s
database, prostate cancer, survival, time to treatment.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Malignant diseases represent considerable clinical, economical,
and humanistic burden in middle- and higher-income countries
[1–3]. There is an increasing social debate on the money spent on
the care of patients with malignant diseases [4], especially
considering some high-priced treatments with marginal health
gain [5]. This is especially true for Central Eastern Europe, with
even more limited health care resources compared with Western
countries [6]. Countries of the region, though, are generally
associated with poorer health status than are countries of West-
ern Europe and North America [7,8], indicating a higher need for
appropriate decisions in prioritizing among interventions and
disease areas [9]. Estimating the clinical burden via epidemiologic
indicators, evaluation of quality indicators of treatment, and
monitoring effectiveness and cost of care are therefore becoming
increasingly important in the region. Burden of disease studies
are suitable to support evidence-based decision making by
identifying unmet need and disease areas for public health careinvestment [10–12]. In Hungary, data to estimate these indicators
are routinely collected in the database of the National Health
Insurance Fund (NHIF) [13].
The aim of this research was to estimate the epidemiological
(occurrence and mortality) and quality (survival and time from
diagnosis to treatment) measures and resource use (annual
health care cost of patient) indicators in Hungary in four malig-
nant conditions (colorectal cancer, lung cancer, breast cancer,
and prostate cancer) from the payer’s database.Methods
The analyses were performed on the NHIF database. Inpatient
or outpatient care patient records containing the following
International Classiﬁcation of Diseases (ICD) [14] codes (main or
supplementary diagnosis) were considered eligible for the study:
C18–C20 (colorectal cancer), C33–C34 (lung cancer), C50 (breast
cancer), and C61 (prostate cancer). Patient records were includedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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there were1. at least two consecutive ICD codes from those listed above,
with a minimum of 30-day difference between their
establishment, or2. one of these ICD codes, and the patient died within 60 days.
Multiple different cancer codes (except for colon þ rectum)
were excluded from the study.
The period 2000 to 2003 was considered as a run-in period in
the estimation of the number of new cases. Because in this period
patients who had their diagnosis established before 2000 might
have received care, their inclusion into this period might have
resulted in an overestimation of the number of new cases.
Therefore, we estimated it only between 2004 and 2011 annually.
The reason for omitting 2012 from the calculation was that
because two occasions of care with the same ICD code were
required over a 30-day interval for inclusion in the study, and
patients receiving care ﬁrst at the end of 2012 and then at the
beginning of 2013 would not have been included in the calcu-
lation of the number of new cases for 2012, it would have resulted
in an underestimation.
Two separate survival analyses were performed by applying
the Kaplan-Meier method in newly diagnosed patients. In the
ﬁrst analysis, death from any cause was considered as an
outcome, whereas in the second analysis, time to the occurrence
of the combined outcome of being either treated or dead was
considered. To estimate the time from diagnosis to treatment,
patients were considered as treated patients who had radio-
therapy/chemotherapy (L01 and partially L02 ATC)/surgery with
the same ICD code as the diagnosis. Epidemiological and quality
measures were compared with the data of the Hungarian Central
Statistical Ofﬁce, the National Cancer Registry, and international
references from the medical literature.
In cost analyses, the following categories were considered:
outpatient cost (including some forms of radiotherapy), inpatient
cost (surgery, chemotherapies from the NHIF manual, other high-
price drugs, radiotherapy, “hotel costs”), sick allowance, cost ofInially excluded: 
233,909 
626,997
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Fig. 1 – Patient ﬂow. ICD, Internatioreimbursed drugs, drug co-payment, cost of computed tomogra-
phy (CT)/magnetic resonance imaging (MRI), cost of high-price
medical devices, diagnostics, and interventions (e.g., positron
emission tomography [PET]/CT), and cost of high-price drugs.
High-price drugs were considered at 80% price to compensate for
the effects of the expected rebate from manufacturers toward
the NHIF.
Costs were segmented into disease- and non–disease-associ-
ated costs. Disease-associated costs included drug cost (with the
same ICD code on the prescription as in the patient’s diagnosis—
available from 2007), inpatient cost (coded with the same ICD
code as the diagnosis), outpatient cost (coded with the same ICD
code as the diagnosis), CT/MRI, and high-price medical devices
(e.g., PET CT) and interventions (coded with the same ICD code as
the diagnosis). However, non–disease-associated cost reﬂected
similar categories, but coded with ICD codes other than those for
the diagnosed condition. Sick allowance was also calculated. In
Hungary, inpatient services are ﬁnanced by the diagnosis related
group (DRG) system and outpatient services are ﬁnanced via
German points. Unit costs of DRG (150,000 HUF in 2011) and
German point (1.5 HUF in 2011) were multiplied by the actual
values of each service utilization documented in the NHIF data-
base and aggregated in this analysis. Cost ﬁgures of the study are
presented at constant 279.21 HUF/1 euro (€) (2011 average
exchange rate); longitudinal cost ﬁgures did not consider inﬂation
(nominal values).
To compare the cost ﬁgures of this study, hemophilia,
another serious condition with high impact on patient’s quality
of life and payer’s health care budget, was selected. Patient
records containing D66–D68 ICD codes from January 1, 2008, to
December 31, 2012, were considered eligible. At least two
occurrences of these ICD codes with a minimum of 30-day gap
were required for inclusion in the study. In addition, the screen-
ing syntax involved those patients who were prescribed factor
products for hemophilia. The following cost categories were
considered for patients with hemophilia: outpatient cost, inpa-
tient cost, drug cost, CT/MRI, high-price medical devices, diag-
nostics, and interventions (e.g., PET CT), and cost of high-price
drugs (at 80%).Breast: 2,186
Prostate: 1,465
Lung: 20,281
Colorectal: 11,840
,772
gnosis: 20,115
ta: 293
Less than 30 days 
between two ICDs 
(177,729):
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The patient ﬂow is described in Fig. 1. Of the 626,997 eligible patient
records (at least one ICD code of the following: C18, C19, C20, C33,
C34, C50, or C61, between January 1, 2000, and December 31, 2012),
233,909 were initially excluded, but 35,772 of these were reincluded
in the sample because the patients died within 60 days (reasons for
exclusion: mixed diagnosis, 20,115; invalid data, 293;o30-day differ-
ence between the two ICD codes, 177,729). The ﬁnal sample
contained 428,860 records (colorectal cancer 106,395 þ 11,840, lung
cancer 106,450 þ 20,281, breast cancer 125,326 þ 2,186, and prostate
cancer 54,917 þ 1,465).
The epidemiological measures (number of new cases [for 2004–
2011] and deaths [for 2011]) from this study and from the National
Cancer Registry and mortality statistics are summarized in Table 1.Table 1 – Number of new cases (2004–2011) and deaths (
Type of
cancer
New cases
2004 2005 2006 2007 2008 2009
Breast cancer
(C50)
7 869 7 838 6 775 6 216 6 465 6 342
Colorectal
cancer
(C18–C20)
8 179 8 318 8 058 7 843 8 357 8 340
Lung cancer
(C33–C34)
9 157 9 149 9 058 8 764 8 971 8 988
Prostate
cancer
(C61)
4 105 3 897 3 463 3 114 3 268 3 497
CSO, Central Statistical Ofﬁce.
Table 2 – 5-y survival probability.
Type of
cancer
Reference studies
Present
study
National Cancer
Registry (Tusnády
et al., 2008),
Hungary [16]
Agüero
et al., 2012
Spain [17]
Time frame 2004–2012
(OS)
2002–2005 (OS) 2003–2007
(OS; speciﬁc
survival)
Breast cancer
(C50)
75.2% 72%–73%
Colorectal
cancer
(C18–C20)
41.3% 30%–40% 48.6%/ 60.4%
Lung cancer
(C33–C34)
17.1% 10%–20%
Prostate
cancer
(C61)
62.1% 52%–60%
OS, overall survival.In 2011 (last complete study year), according to our analysis, there
were 6381 new breast cancer, 8457 new colorectal cancer, 8902 new
lung cancer, and 3419 new prostate cancer cases in Hungary. The
numbers of patients who suffered from these diseases and died
were 3741, 6282, 8317, and 2412, respectively.
Tables 2 and 3 indicate the quality indicators of the treatment
(probability of 5-year overall survival [OS] [%] and time from
diagnosis to treatment) together with benchmark results from
the literature. Data suggest that breast and prostate cancers were
associated with the highest probability of 5-year OS (75.2% and
62.1%, respectively) whereas the prognosis of colorectal and lung
cancers was poor (probability of 5-year OS 41.3% and 17.1%,
respectively) (Table 2). The median time from diagnosis to treat-
ment was less than 1 month in all conditions (breast cancer 29
days, colorectal cancer 23 days, and prostate cancer 21 days)
except for lung cancer (50 days) (Table 3).2011).
Newly
diagnosed
cases
(National
Cancer
Registry)
(2011)
No. of
deaths in
patients
with
malignant
condition
(2011)
Cause of
death
statistics
(CSO)
(2011)
2010 2011
6 439 6381 7,329 3741 2138
8 231 8457 10,658
(C18–C21)
6282
(C18–C20)
5054
(C18–C21)
8 747 8902 11,706 (C34) 8317 8533
3 584 3419 4,368 2412 1198
(country, year of publication)
,
Deleuran
et al.,
2013,
Denmark
[18]
DeSantis
et al.,
2014,
USA [21]
Marcos-
Gragera
et al.,
2012,
Spain [19]
Nguyen-
Nielsen
et al., 2013,
Denmark
[20]
2009–2011
(OS)
2003–2009
(cause-
speciﬁc
survival)
2000–2003
(OS)
2009–2011
(OS)
88.6%
13%
67.4% 65%
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 7 C ( 2 0 1 5 ) 1 – 84Figure 2 shows the percentage of treated patients and risk of
death from any cause among patients with a ﬁrst diagnosis of the
malignant condition as a function of time by disease. Among
patients with breast cancer, at 1 month, 47% of the patients
received no treatment, 51.6% (52.3% among those who were alive)
were treated, and the 1-month risk of death was 1.4%. In patients
with a ﬁrst diagnosis of prostate cancer, these ﬁgures were 40.5%,
58% (58.9%), and 1.5%, respectively. The 1-month risk of death in
patients with the ﬁrst diagnosis of colorectal cancer was 7.7%,
and 37.7% of them were untreated, while 54.6% received treat-
ment (59.2% of those who were alive were treated) within the ﬁrst
month. These indicators were worse in patients with lung cancer:
the 1-month risk of death was 13.9%, and 56.1% of them received
no treatment in the ﬁrst month, while 30.0% of the patients were
treated (34.8% of those who were alive).
Table 4 presents the detailed longitudinal cost structure of
patients for 2005, 2008, and 2011 (last complete study year) paid
by the NHIF. In 2011, the annual cost of the NHIF for an average
patient was €3165 (in colorectal cancer), €2585 (in breast cancer),
€2834 (in prostate cancer), and €4157 (in lung cancer), respec-
tively. Disease-associated costs were higher in all malignancies
than non–disease-associated costs (colorectal cancer €1920 vs.
€1151, breast cancer €1550 vs. €949, prostate cancer €1582 vs.
€1222, and lung cancer €2544 vs. €1462, respectively) in 2011.
Overall costs were highest in 2008 except for lung cancer and
were higher in 2011 than in 2005 in all conditions except for
prostate cancer. The number of treated patients was 41,967 (in
colorectal cancer), 64,801 (in breast cancer), 24,472 (in prostate
cancer), and 20,550 (in lung cancer) in 2011, respectively. By
multiplying the number of treated patients with the annual cost
of NHIF per patient, the overall NHIF expenditure on the four
malignancies was calculated. In 2011, the NHIF expenditure for
patients with one of the four conditions reached €132.82 million
(in colorectal cancer), €167.51 million (in breast cancer), €69.35
million (in prostate cancer), and €85.42 million (in lung cancer),
respectively. The annual cost of patients with hemophilia was
applied as benchmark. Within the €8284 annual cost, in 2011, the
highest amount was the cost of hemophilia factor products
(€7207), followed by drug costs (€531 ), and costs of inpatient
(€336) and outpatient (€124) care.Discussion
According to our results, lung cancer was associated with the
poorest prognosis among the observed four malignant condi-
tions. Moreover, quality indicators were the worse in lung cancer,
while this condition was associated with the highest annual cost.
The method used for participant selection had some limita-
tions in this study. Patients were included on the basis of ﬁrst
occurrence of the respective ICD codes in their health service
utilization ﬁles. This does not necessarily imply that patients had
a deﬁnitive diagnosis. To reduce the chance that patients who
had diagnostic workup toward the studied malignancies but
actually did not have these diseases would be included, two
occasions of health service utilization were required with the
same ICD code with at least 30 days between the two occasions,
or if the patients died within 60 days. Although it increased the
speciﬁcity of the selection, the possibility remained that some
patients might have been included in the study without a
relevant condition (false-positive patients). However, patients
with end-stage disease, who died more than 60 days after the
ﬁrst service use without contacting the health service again, after
a month, were not included. The number of these persons is
likely to be very small.
The external validity of data presented in this study was
assessed by comparing the results with relevant Hungarian
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Fig. 2 – Overall survival analyses of the four malignant conditions (death from any causes).
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Cancer Registry) and with published references of the medical
literature. The number of new cases reported in this study was
lower than that reported by the Hungarian Central Statistical
Ofﬁce on the basis of the National Cancer Registry for 2011. This
provides evidence that our estimate is conservative. Our selection
procedure described above was speciﬁc but not very sensitive
(Table 1). Regarding colorectal cancer, the difference is partly
because the C21 ICD code was not included among the selection
criteria of our analysis, although it is included in the ofﬁcial
colorectal cancer statistics. The number of new cases reported by
Boncz et al. [15] in colorectal cancer (4677 males and 4085 females
in 2001) using the NHIF database is similar to our results.
Longitudinal trends in the number of new cases from 2004 to
2011 should be interpreted with care because the run-in screen-
ing period to exclude prevalent cases was 7 years longer in 2011
than in 2004, indicating a false decreasing trend.
The number of deaths of patients receiving care for the
studied malignancies was higher than the mortality due to these
cancers reported by the Hungarian Central Statistical Ofﬁce. It is
consistent with the expectations because not all patients with
cancer die of cancer. The difference was the smallest in case of
lung cancer, indicating that this type of cancer has the poorest
prognosis of the four studied malignancies.
Compared with the National Cancer Registry [16], this study
provides a good estimate for probability of 5-year OS (Table 2),
and it is also in concordance with other data published in the
medical literature [17–21]. The 5-year OS probability of breastcancer and especially colorectal cancer appears to be somewhat
worse than some international references. Direct comparison of
the OS probabilities requires caution because no information was
available about relevant patient characteristics that may have
affected survival.
Timely access to appropriate treatment is critical in oncology,
especially in conditions with rapid progression such as colorectal
or lung cancer. Signiﬁcant delays in treatment initiation may
result in progression of the disease, and therefore may be
considered as a cause of wasting scarce resources. According to
Table 3, there is still room to improve the timeliness of lung
cancer treatment initiation (median 50 days), while the time lag
between the ﬁrst care marked with a relevant ICD code and the
initiation of treatment can be considered fair for the three other
conditions. Still, treatment delay indicators reported by Hansen
et al. [22] have been better in all four conditions in Denmark than
in Hungary. In that study, similarly to our results, lung cancer
was associated with the highest median treatment delay among
the four malignant conditions with 23 days. Macià et al. [23] have
reported data from Spain with better median values for lung
cancer but worse indicators for the treatment of breast and
prostate cancers compared with Hungary. Median data reported
by Esteva et al. [24] in colorectal cancer have been similar to our
results. Further ﬁgures are also available for colorectal cancer [25]
and lung cancer [26–28] in the literature; however, these studies
report median data on treatment delay from ﬁrst suspicion/visit/
symptom onset instead of ﬁrst diagnosis; therefore, they result in
higher delays.
Table 4 – Average cost (€) of National Health Insurance Fund per patient with the four malignancies in 2005, 2008, and 2011.
Cost (€) Breast cancer Colorectal cancer Lung cancer Prostate cancer
2005 2008 2011 2005 2008 2011 2005 2008 2011 2005 2008 2011
Disease-related cost
Drug reimbursement 0 756 450 0 85 82 0 422 560 0 422 1156
Drug co-payment 0 15 9 0 6 5 0 17 14 0 17 15
Inpatient cost 572 820 650 1354 2062 1392 1486 1802 1457 1486 1802 335
Outpatient cost 66 77 70 35 49 41 37 54 51 38 52 56
CT 15 23 24 31 51 47 45 55 49 45 55 20
High-price medical devices and interventions 4 23 29 33 55 63 36 68 83 36 68 0
High-price drugs (at 80%) 0 195 317 0 0 289 0 0 330 0 0 0
Total disease-related cost 658 1908 1550 1453 2308 1920 1603 2417 2544 1605 2416 1582
Non–disease-related cost
Drug reimbursement 1045 368 440 630 417 446 630 538 683 630 538 498
Drug co-payment 79 89 93 88 98 103 70 83 92 70 83 134
Inpatient cost 268 277 284 476 441 438 471 509 502 471 509 452
Outpatient cost 100 98 97 94 94 95 78 88 94 76 89 96
CT 23 24 23 48 49 43 58 65 58 58 65 20
High-price medical devices and interventions 6 10 12 23 19 27 24 33 32 24 33 22
High-price drugs (at 80%) 0 0 0 0 0 0 0 0 0 0 0 0
Total non–disease-related cost 1521 867 949 1359 1119 1151 1329 1316 1462 1328 1317 1222
Sick allowance 112 126 86 120 130 94 205 211 151 205 211 29
Total cost 2292 2901 2585 2932 3556 3165 3137 3944 4157 3137 3944 2834
CT, computed tomography.
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 7 C ( 2 0 1 5 ) 1 – 8 7To facilitate weighing the cost of care of a patient with cancer,
we compared it with the cost of care of a patient with hemo-
philia. We selected hemophilia because it is a similarly severe
disease, and it strongly affects the quality of life of patients and
their caregivers. Furthermore, the budget impact of the care of
patients with hemophilia has recently been a topic of public
debate on health care costs, just like the cost of care of patients
with malignancies. As compared with the data given in Table 4,
the annual NHIF cost of a patient with hemophilia was twice as
much as of a patient suffering from lung cancer, the condition
associated with the highest annual cost among the observed four
malignancies in 2011.
According to the report of Boncz et al. [15], in 2001, €38.871
million was spent on colorectal cancer treatment of 40,057 out-
patients and 10,187 inpatients, indicating an annual per capita
cost of €774, which is less than a quarter of our estimate 10 years
later. Direct comparison of cost data reported in this study with
previous Hungarian reports, however, is difﬁcult because many
potentially relevant articles reported aggregated data on the
entire budget for each condition without indicating the number
of treated patients [29–31]. The NHIF spent in total €4347 million
on curative and preventive health care, drug reimbursement, and
sick allowance in 2011 [32]. According to our analyses, NHIF
expenditures on patients with the four malignancies reached a
share of 3.06% (in colorectal cancer), 3.85% (in breast cancer), 1.6%
(in prostate cancer), and 1.96% (in lung cancer) in 2011,
respectively.
The real drug cost of the payer is less than the data we
presented because of the additional contributions of pharma-
ceutical companies. There is an obligatory contribution after
reimbursed products sold in pharmacies, amounting to 20% of
the reimbursement amount calculated on ex-manufacturers’
price level, and an additional 10% tax for those innovative drugs
with a history of at least 6 years of reimbursement and without
reimbursed generic alternative in Hungary. New innovative drugs
can be involved into the reimbursement system only with a risk-
sharing scheme including price volume agreement. Manufac-
turers may also offer free drugs for hospitals. Also, in many
countries, sick allowance is not within the responsibility of the
health care system; therefore, in conclusion, because of these
factors, our ﬁgures may overestimate the real costs compared
with international references.
However, in the past 5 years, the government provided extra
ﬁnancing for hospitals to settle their cost overrun, which is not
included in the activity-based ﬁnancing (e.g., in DRGs or fee-for-
service ambulatory payments); therefore, our ﬁgures may under-
estimate the real costs. These factors also limit the comparability
of our ﬁndings with international references.
Strengths and Weaknesses of the Study
This analysis is based on a payer’s database that contains records
that have ﬁnancial consequences for the payer; therefore, it may
have limitations to capture all the relevant costs for a condition.
In addition, ﬁnancial incentives for health care providers might
have caused biases in the reporting. Unfortunately, the NHIF
provides only aggregate results to protect privacy of personal
data, which prevented us from conducting multiple regression
analysis. Without data on disease population characteristics,
such as age and case-mix, comparability and interpretability of
our results with other published references is limited. Further
research in the future could address the suitability of the NHIF
database to provide more detailed data on patients, procedures,
interventions, and outcomes such as disease-speciﬁc survival in
speciﬁc disease groups. Linking health service utilization data
with the data of the National Cancer Registry would provide
valuable additional opportunities for more detailed analyses.Policy Implications of the Study
In addition to clinical trials, complementary evidence is needed
to evaluate the effectiveness of reimbursed treatments and care
in oncology. The NHIF database is suitable for estimating epi-
demiological and quality measures and resource use indicators.
These types of analyses can support long-term evidence-based
policymaking by evaluating the outcomes of health investment
decisions in oncology. Real-world evidence can also increase the
validity of value propositions of new medicines in the Central
Eastern Europe region.Conclusions
This article summarized some epidemiological and quality meas-
ures and economic indicators of the care of patients with color-
ectal cancer, lung cancer, breast cancer, and prostate cancer on
the basis of NHIF data in Hungary. The 5-year survival estimates
of this study were in accordance with the National Cancer
Registry data and further international references. The time
spent from establishing the diagnosis to treatment was fair in
all conditions, except for lung cancer. Disease-associated costs
were higher than non–disease-associated costs in all malignant
conditions. The annual per capita costs of care of patients with
the studied malignancies were less than half of the annual costs
of a patient with hemophilia. The results indicated that the
database of the Hungarian NHIF is suitable for real-world data
analysis in the ﬁeld of oncology.Acknowledgments
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